Glucose Health, Inc. Logo

Glucose Health, Inc.

GLUC

(2.0)
Stock Price

0,12 USD

-131.58% ROA

-161.78% ROE

-8.26x PER

Market Cap.

2.909.052,00 USD

0% DER

0% Yield

-74.98% NPM

Glucose Health, Inc. Stock Analysis

Glucose Health, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Glucose Health, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (92.94%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0.6x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-71%), which means it has a small amount of debt compared to the ownership it holds

4 Assets Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

5 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

6 ROA

The stock's ROA (-1247.36%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Glucose Health, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Glucose Health, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Glucose Health, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Glucose Health, Inc. Revenue
Year Revenue Growth
2007 37.951
2008 51.647 26.52%
2009 30.425 -69.75%
2010 2.406 -1164.55%
2011 0 0%
2012 0 0%
2013 224 100%
2014 2.739 91.82%
2015 4.272 35.88%
2016 313.229 98.64%
2017 104.522 -199.68%
2018 274.956 61.99%
2018 197.500 -39.22%
2019 291.213 32.18%
2020 480.713 39.42%
2021 953.681 49.59%
2022 1.072.655 11.09%
2023 534.724 -100.6%
2024 451.916 -18.32%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Glucose Health, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 4.000 100%
2015 48 -8233.33%
2016 0 0%
2017 0 0%
2018 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 10.000 100%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Glucose Health, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 86.459
2008 501.903 82.77%
2009 924.361 45.7%
2010 530.394 -74.28%
2011 0 0%
2012 361.423 100%
2013 1.067.193 66.13%
2014 520.491 -105.04%
2015 156.570 -232.43%
2016 105.814 -47.97%
2017 0 0%
2018 48.852 100%
2018 0 0%
2019 0 0%
2020 143.796 100%
2021 139.225 -3.28%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Glucose Health, Inc. EBITDA
Year EBITDA Growth
2007 -64.653
2008 -512.606 87.39%
2009 -868.460 40.98%
2010 -531.341 -63.45%
2011 -803.524 33.87%
2012 -361.423 -122.32%
2013 -1.048.284 65.52%
2014 -445.118 -135.51%
2015 -133.718 -232.88%
2016 -86.587 -54.43%
2017 -59.780 -44.84%
2018 75.380 179.3%
2018 -23.440 421.59%
2019 -230.050 89.81%
2020 -564.300 59.23%
2021 -336.120 -67.89%
2022 -562.120 40.2%
2023 -421.950 -33.22%
2024 -368.160 -14.61%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Glucose Health, Inc. Gross Profit
Year Gross Profit Growth
2007 21.806
2008 -10.703 303.74%
2009 11.930 189.72%
2010 -947 1359.77%
2011 0 0%
2012 0 0%
2013 -2.091 100%
2014 -20.725 89.91%
2015 397 5320.4%
2016 19.167 97.93%
2017 45.112 57.51%
2018 124.172 63.67%
2018 52.818 -135.09%
2019 52.700 -0.22%
2020 173.545 69.63%
2021 410.042 57.68%
2022 456.715 10.22%
2023 215.752 -111.69%
2024 66.716 -223.39%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Glucose Health, Inc. Net Profit
Year Net Profit Growth
2007 -64.653
2008 -529.289 87.78%
2009 -917.627 42.32%
2010 -632.742 -45.02%
2011 -899.186 29.63%
2012 -399.078 -125.32%
2013 -1.459.146 72.65%
2014 -669.409 -117.98%
2015 -266.064 -151.6%
2016 -410.443 35.18%
2017 24.531 1773.16%
2018 59.728 58.93%
2018 -47.053 226.94%
2019 -246.150 80.88%
2020 -581.443 57.67%
2021 -338.904 -71.57%
2022 -562.116 39.71%
2023 -421.953 -33.22%
2024 -368.152 -14.61%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Glucose Health, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 -4
2008 -23 81.82%
2009 -30 24.14%
2010 -17 -70.59%
2011 -12 -41.67%
2012 -3 -500%
2013 -5 50%
2014 -1 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Glucose Health, Inc. Free Cashflow
Year Free Cashflow Growth
2007 -104.396
2008 -244.559 57.31%
2009 -104.979 -132.96%
2010 -109.639 4.25%
2011 -23.302 -370.51%
2012 -83.691 72.16%
2013 -131.985 36.59%
2014 -135.352 2.49%
2015 -115.776 -16.91%
2016 -39.263 -194.87%
2017 -58.136 32.46%
2018 -82.223 29.29%
2018 50.248 263.63%
2019 -234.255 121.45%
2020 -72.232 -224.31%
2021 -72.739 0.7%
2022 -389.154 81.31%
2023 -243.785 -59.63%
2024 -94.413 -158.21%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Glucose Health, Inc. Operating Cashflow
Year Operating Cashflow Growth
2007 -104.396
2008 -182.984 42.95%
2009 -104.979 -74.31%
2010 -109.639 4.25%
2011 -23.302 -370.51%
2012 -83.691 72.16%
2013 -131.985 36.59%
2014 -135.352 2.49%
2015 -115.776 -16.91%
2016 -39.263 -194.87%
2017 -58.136 32.46%
2018 -82.223 29.29%
2018 50.248 263.63%
2019 -234.255 121.45%
2020 -68.937 -239.81%
2021 -72.739 5.23%
2022 -389.154 81.31%
2023 -243.785 -59.63%
2024 -94.413 -158.21%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Glucose Health, Inc. Capital Expenditure
Year Capital Expenditure Growth
2007 0
2008 61.575 100%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2018 0 0%
2019 0 0%
2020 3.295 100%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Glucose Health, Inc. Equity
Year Equity Growth
2007 65.167
2008 25.569 -154.87%
2009 -301.123 108.49%
2010 -594.573 49.35%
2011 -186.022 -219.63%
2012 22.200 937.94%
2013 -197.758 111.23%
2014 -280.552 29.51%
2015 -387.819 27.66%
2016 -495.447 21.72%
2017 -432.557 -14.54%
2018 -376.007 -15.04%
2018 -470.759 20.13%
2019 -160.927 -192.53%
2020 41.088 491.66%
2021 1.146.552 96.42%
2022 577.090 -98.68%
2023 257.724 -123.92%
2024 137.145 -87.92%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Glucose Health, Inc. Assets
Year Assets Growth
2007 79.448
2008 194.609 59.18%
2009 165.386 -17.67%
2010 87.791 -88.39%
2011 233.682 62.43%
2012 207.676 -12.52%
2013 25.590 -711.55%
2014 44.030 41.88%
2015 15.407 -185.78%
2016 33.145 53.52%
2017 26.931 -23.07%
2018 141.797 81.01%
2018 89.235 -58.9%
2019 219.725 59.39%
2020 344.616 36.24%
2021 1.156.107 70.19%
2022 598.126 -93.29%
2023 398.772 -49.99%
2024 268.435 -48.55%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Glucose Health, Inc. Liabilities
Year Liabilities Growth
2007 14.281
2008 169.040 91.55%
2009 466.509 63.76%
2010 682.364 31.63%
2011 419.704 -62.58%
2012 185.476 -126.28%
2013 223.348 16.96%
2014 324.582 31.19%
2015 403.226 19.5%
2016 528.592 23.72%
2017 459.488 -15.04%
2018 517.804 11.26%
2018 559.995 7.53%
2019 380.652 -47.11%
2020 303.527 -25.41%
2021 9.555 -3076.63%
2022 21.036 54.58%
2023 141.048 85.09%
2024 131.290 -7.43%

Glucose Health, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.03
Net Income per Share
-0.02
Price to Earning Ratio
-8.26x
Price To Sales Ratio
6.18x
POCF Ratio
-10.76
PFCF Ratio
-10.73
Price to Book Ratio
21.27
EV to Sales
5.97
EV Over EBITDA
-7.96
EV to Operating CashFlow
-10.36
EV to FreeCashFlow
-10.36
Earnings Yield
-0.12
FreeCashFlow Yield
-0.09
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.06
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.77
ROE
-1.62
Return On Assets
-1.32
Return On Capital Employed
-2.58
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-0.75
Effective Tax Rate
0.4

Margins

Sales, General, & Administrative to Revenue
0.1
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.29
Operating Profit Margin
-0.75
Pretax Profit Margin
-0.75
Net Profit Margin
-0.75

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.05
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-2.23
Return on Tangible Assets
-1.32
Days Sales Outstanding
9.4
Days Payables Outstanding
37.02
Days of Inventory on Hand
169.99
Receivables Turnover
38.85
Payables Turnover
9.86
Inventory Turnover
2.15
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,01
Tangible Book Value per Share
0.01
Shareholders Equity per Share
0.01
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.28
Current Ratio
2.02
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
133850
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
149904.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Glucose Health, Inc. Dividends
Year Dividends Growth

Glucose Health, Inc. Profile

About Glucose Health, Inc.

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.

CEO
Mr. Murray S. Fleming
Employee
3
Address
609 SW 8th Street
Bentonville, 72712

Glucose Health, Inc. Executives & BODs

Glucose Health, Inc. Executives & BODs
# Name Age
1 Mr. Murray S. Fleming
Chief Executive Officer, Chief Financial Officer & Director
70
2 Ms. Peggy Knight
Advisor of Marketing & Branding
70

Glucose Health, Inc. Competitors